CNBX Pharmaceuticals reported a non-revenue QQ1 2025 quarter, continuing a pattern of early-stage biotech spend with no top-line contribution. Operating losses persisted with an -36,837 EBITDA and a -34,352 net income, translating to basic EPS of -0.0011. The company burned cash from operations (-39,077) while securing a net financing inflow of +30,000, leaving cash at period-end of 17,339. The liquidity runway is therefore highly dependent on external financing or near-term monetization events tied to the RCC33 and Cannabics pipelines.
From a balance-sheet perspective, CNBX presents a precarious financial position: total current liabilities of 2,536,640 dwarf cash and cash equivalents of 17,339, and a negative stockholders’ equity of -2,514,332. The current ratio sits at approximately 0.0088, signaling meaningful liquidity risk absent additional funding. Net debt stands at 1,310,893, underscoring leverage constraints in a capital-intensive biotech space. Given the lack of revenue generation and absent explicit guidance, the company’s near-term value creation hinges on successful clinical milestones, licensing transactions, or partnerships that could monetize its Cannabics SR/CDx platform and lead RCC33 programs. Management commentary from the earnings call is not provided in the data set, limiting qualitative insight into roadmap pivots or anticipated financing plans; investors should monitor RCC33 data readouts, collaboration discussions, and any newly disclosed capital-raising activities.